|
US4663327A
(en)
*
|
1984-05-23 |
1987-05-05 |
Bayer Aktiengesellschaft |
1-heteroaryl-4-aryl-pyrazolin-5-ones
|
|
DE3443308A1
(de)
*
|
1984-11-28 |
1986-05-28 |
Bayer Ag, 5090 Leverkusen |
1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
|
|
DE3527157A1
(de)
|
1985-07-30 |
1987-02-12 |
Bayer Ag |
1-heteroaryl-4-aryl-pyrazol-derivate
|
|
DE4023488A1
(de)
|
1990-07-24 |
1992-01-30 |
Bayer Ag |
1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
|
|
CA2138929A1
(en)
|
1993-12-30 |
1995-07-01 |
Klaus Weidmann |
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
|
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
|
CN102351791B
(zh)
|
2006-01-27 |
2014-10-29 |
菲布罗根有限公司 |
使低氧诱导因子(hif)稳定的氰基异喹啉化合物
|
|
NZ623002A
(en)
|
2006-06-26 |
2015-08-28 |
Akebia Therapeutics Inc |
Prolyl hydroxylase inhibitors and methods of use
|
|
US20090011051A1
(en)
|
2006-09-28 |
2009-01-08 |
Roth Mark B |
Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
|
|
DE102006050513A1
(de)
|
2006-10-26 |
2008-04-30 |
Bayer Healthcare Ag |
Substitiuierte Dihydropyrazolone und ihre Verwendung
|
|
DE102006050512A1
(de)
*
|
2006-10-26 |
2008-04-30 |
Bayer Healthcare Ag |
Substituierte heterocyclische Verbindungen und ihre Verwendung
|
|
DE102006050516A1
(de)
*
|
2006-10-26 |
2008-04-30 |
Bayer Healthcare Ag |
Substituierte Dihydropyrazolone und ihre Verwendung
|
|
DE102006050515A1
(de)
|
2006-10-26 |
2008-04-30 |
Bayer Healthcare Ag |
Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
|
|
WO2008121861A2
(en)
|
2007-03-28 |
2008-10-09 |
Xenon Pharmaceuticals Inc. |
Pyrazole and pyrrole compounds useful in treating iron disorders
|
|
DE102007044032A1
(de)
*
|
2007-09-14 |
2009-03-19 |
Bayer Healthcare Ag |
Substituierte heterocyclische Verbindungen und ihre Verwendung
|
|
WO2010005851A1
(en)
*
|
2008-07-08 |
2010-01-14 |
Xenon Pharmaceuticals Inc. |
Combination therapy for treating iron disorders
|
|
SG172803A1
(en)
|
2008-12-29 |
2011-08-29 |
Sanofi Sa |
Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
|
|
NO2686520T3
(cg-RX-API-DMAC10.html)
|
2011-06-06 |
2018-03-17 |
|
|
|
WO2013134660A1
(en)
|
2012-03-09 |
2013-09-12 |
Fibrogen, Inc. |
4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
|
|
US8987461B2
(en)
*
|
2012-12-06 |
2015-03-24 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
|
AP2015008783A0
(en)
|
2013-03-29 |
2015-10-31 |
Takeda Pharmaceutical |
6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
|
|
GB201504565D0
(en)
|
2015-03-18 |
2015-05-06 |
Takeda Pharmaceutical |
Novel compounds
|
|
US11510917B2
(en)
|
2016-02-19 |
2022-11-29 |
Cornell University |
HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
|
|
CN106831735B
(zh)
|
2017-01-23 |
2019-10-11 |
牡丹江医学院 |
一种治疗骨质疏松的杂环化合物及其制备方法和用途
|
|
CN109879804B
(zh)
|
2019-01-30 |
2022-06-17 |
中国药科大学 |
5-杂环取代吡啶-2-甲酰甘氨酸化合物、其制法和医药用途
|
|
EP4121425A1
(en)
|
2020-03-20 |
2023-01-25 |
Akebia Therapeutics Inc. |
Phd inhibitor compounds, compositions, and use
|
|
KR20220156890A
(ko)
|
2020-03-20 |
2022-11-28 |
아케비아 테라퓨틱스 인코포레이티드 |
Phd 억제제 화합물, 조성물, 및 용도
|
|
AR121626A1
(es)
|
2020-03-20 |
2022-06-22 |
Akebia Therapeutics Inc |
Compuestos inhibidores de phd, composiciones y métodos de uso
|
|
WO2021216530A1
(en)
|
2020-04-20 |
2021-10-28 |
Akebia Therapeutics, Inc. |
Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
|
|
EP4196466A1
(en)
|
2020-08-14 |
2023-06-21 |
Akebia Therapeutics Inc. |
Phd inhibitor compounds, compositions, and methods of use
|